Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.31 |
| ▸ | CTSL | P07711 | 2/20 | 0.31 |
| ▸ | CTSS | P25774 | 2/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7735809 | 1.00 | L3MBTL1 (0.35) | L3MBTL1CHRM3GRM2MCHR1TLR9 | |
| SCHEMBL7735800 | 1.00 | L3MBTL1 (0.35) | L3MBTL1CHRM3GRM2MCHR1TLR9 | |
| SCHEMBL7737016 | 0.88 | L3MBTL1 (0.39) | L3MBTL1GRM2MCHR1HRH3 | |
| SCHEMBL7737012 | 0.88 | L3MBTL1 (0.39) | L3MBTL1GRM2MCHR1HRH3 | |
| SCHEMBL7737020 | 0.88 | L3MBTL1 (0.39) | L3MBTL1GRM2MCHR1HRH3 | |
| SCHEMBL9346475 | 0.84 | L3MBTL1 (0.39) | L3MBTL1TLR9TLR8TLR7HRH3 | |
| SCHEMBL7728062 | 0.82 | CTSL (0.35) | L3MBTL1CTSLCTSSCTSK | |
| SCHEMBL7728079 | 0.82 | CTSL (0.35) | L3MBTL1CTSLCTSSCTSK | |
| SCHEMBL7728071 | 0.82 | CTSL (0.35) | L3MBTL1CTSLCTSSCTSK | |
| SCHEMBL9346373 | 0.80 | L3MBTL1 (0.41) | L3MBTL1TLR9TLR8TLR7HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458433-B1 | ISOTOPE REPLACEMENT; OPTICAL DISPLAY | CHISSO CORPORATION (JP) | 2002-10-01 | — | — | US | disclosed |
| US-20020038858-A1 | Isotope replacement; optical display | JNC CORPORATION (JP) | 2002-04-04 | — | — | US | disclosed |
| EP-0949232-A1 | DIFLUOROPHENYL DERIVATIVES, LIQUID-CRYSTAL COMPOUNDS, AND LIQUID-CRYSTAL COMPOSITION | CHISSO CORPORATION (JP) | 1999-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038858-A1 | Isotope replacement; optical display | IRS1, FES, IK | L3MBTL1 362/4885CHRM3 1931/4885GRM2 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.